Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec;18(6):546-56.
doi: 10.1016/j.copbio.2007.10.010. Epub 2007 Dec 11.

Replicating and non-replicating viral vectors for vaccine development

Affiliations
Review

Replicating and non-replicating viral vectors for vaccine development

Marjorie Robert-Guroff. Curr Opin Biotechnol. 2007 Dec.

Abstract

Viral vectors provide a convenient means to deliver vaccine antigens to select target cells or tissues. A broad spectrum of replicating and non-replicating vectors is available. An appropriate choice for select applications will depend on the biology of the infectious agent targeted, as well as factors such as whether the vaccine is intended to prevent infection or boost immunity in already infected individuals, prior exposure of the target population to the vector, safety, and the number and size of gene inserts needed. Here several viral vectors under development as HIV/AIDS vaccines are reviewed. A vaccine strategy based on initial priming with a replicating vector to enlist the innate immune system, target mucosal inductive sites, and prime both cellular and humoral systemic and mucosal immune responses is proposed. Subsequently, boosting with a replicating or non-replicating vector and/or protein subunits could lead to induction of necessary levels of protective immunity.

PubMed Disclaimer

References

    1. Plotkin S.A., Orenstein W.A. Saunders; 2004. Vaccines.
    1. Liniger M., Zuniga A., Naim H. Use of viral vectors for the development of vaccines. Expert Rev Vaccines. 2007;6:255–266. - PubMed
    1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 1998;392:245–252. - PubMed
    1. Robert-Guroff M, Nabel GJ, Shiver JW: Replication-defective and competent adenovirus recombinants as vaccine vectors. In New Generation Vaccines, edn 4. Edited by Levine MM. Informa Healthcare; 2007, in press.
    2. Comprehensive update on use of adenovirus recombinants in HIV vaccine research.

    1. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M.-E., Evans R.K., Zhang Z.-Q., Simon A.J., Trigona W.L., Dubey S.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331–335. - PubMed

Publication types